Radiologic screening and surveillance in hereditary cancers

Jamie E Clarke; Stephanie Magoon; Irman Forghani; Francesco Alessandrino; Gina D'Amato; Emily Jonczak; Ty K Subhawong

doi:10.1016/j.ejro.2022.100422

Radiologic screening and surveillance in hereditary cancers

Eur J Radiol Open. 2022 Apr 25:9:100422. doi: 10.1016/j.ejro.2022.100422. eCollection 2022.

Authors

Jamie E Clarke^{1

2}, Stephanie Magoon¹, Irman Forghani³, Francesco Alessandrino², Gina D'Amato⁴, Emily Jonczak⁴, Ty K Subhawong²

Affiliations

¹ Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA.
² Department of Radiology, Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL 33136, USA.
³ Department of Human Genetics, Miller School of Medicine, Miami, FL 33136, USA.
⁴ Department of Hematology/Oncology, Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL 33136, USA.

Abstract

Hereditary cancer syndromes comprise an important subset of cancers caused by pathogenic germline mutations that can affect various organ systems. Radiologic screening and surveillance for solid tumors has emerged as a critical component of patient management in permitting early cancer detection. Although imaging surveillance may be tailored for organ-specific cancer risks, surveillance protocols frequently utilize whole-body MRI or PET/CT because of their ability to identify neoplasms in different anatomic regions in a single exam. In this review, we discuss the basic tenets of imaging screening and surveillance strategies in these syndromes, highlighting the more common neoplasms and their associated multimodality imaging findings.

Keywords: Hereditary cancers; MRI; PET/CT; Radiology; Screening; Surveillance; Whole-body MRI.